Treatment options for patients with chronic lymphocytic leukemia (CLL) are expanding, with a focus on the use of BTK inhibitors and other therapies. The approval of a medication called Jaypirca has been reported, with its use potentially expanding into earlier treatment of the disease. The optimal sequencing and management of these treatments, including the use of BTK inhibitors and other therapies, is an area of ongoing discussion and guidance in the medical community.